$ALT

Durso Jerome Benedict (President and CEO) purchased 15,000 shares of Altimmune, Inc. (ALT) at $2.95 on 2026-08-13.

Altimmune (NASDAQ:ALT) said patients on GLP-1 therapies at antidiabetic doses may be included in its PERFORMA trial, but those on Rezdiffra will be excluded to protect a 52-week biopsy endpoint. PERFORMA 52-week data are expected in 2029. In Phase II AUD RECLAIM, pemvidutide met primary and secondary endpoints, including a 9.1% body-weight reduction. Q2 net loss was $22.8M and cash was $519M.

Altimmune (Nasdaq: ALT) reported Q2 2026 results and a business update. The company initiated the global PERFORMA Phase 3 MASH trial, reported positive topline RECLAIM Phase 2 AUD data, and completed enrollment in the RESTORE Phase 2 ALD trial. Cash, cash equivalents and investments were $519 million as of June 30, 2026. R&D was $18.7 million and net loss $22.8 million.

Altimmune, Inc. (ALT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 alt-20260812xex99d1.htm EX-99.1 Exhibit 99.1 Altimmune Announces Second Quarter 2026 Financial Results and Business Update ​ Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in

U.S. stock index futures edged higher ahead of July CPI at 8:30 a.m. ET. Economists expect +0.2% m/m and 3.4% y/y. Nasdaq futures were up 0.4% and S&P 500 up 0.1% by 4:00 a.m. ET. Pre-market movers included CRWV (+15%), NBIS (+8%), SMCI (+9%), and ORCL (+1%).

Altimmune (NASDAQ:ALT) reported Phase II results for pemvidutide in alcohol use disorder. The WHO risk-drinking-level endpoint improved in 64.4% vs 34.8% on placebo (p=0.0049), and zero heavy drinking days increased with p=0.0066. PEth fell by 175.3 ng/mL vs unchanged on placebo (p=0.0001). Safety was generally tolerable; Phase III AUD discussions with regulators are next.

Altimmune said its RECLAIM Phase 2 trial of pemvidutide for moderate to severe alcohol use disorder met the primary endpoint, with 2.4 mg producing a statistically significant reduction in heavy drinking days per week versus placebo over 24 weeks (treatment effect 1.45 days). It also met secondary endpoints, and the company plans an End-of-Phase 2 meeting with the FDA. Shares rose 11.5% pre-open.

Altimmune Inc. (NASDAQ:ALT) shares rose 18% after it reported positive topline results from its RECLAIM Phase 2 trial of pemvidutide for alcohol use disorder. The study met its primary endpoint with a statistically significant reduction in heavy drinking days versus placebo (4.20 vs 2.75 per week at week 24, p=0.0014). Secondary endpoints and safety data were also favorable, and the company plans an FDA End-of-Phase 2 meeting.

The article says the U.S. anti-obesity drug market is expanding, with the global GLP-1 market reaching $79B in 2025 and projected by Morgan Stanley to exceed $190B by 2035. It cites January 2026 oral Wegovy pill uptake and Medicare/Medicaid BALANCE plans to cap out-of-pocket costs at $50/month. It also notes DOJ scrutiny of compounded formulations and lists 10 stocks, including Altimmune (H.C. Wainwright cut ALT target to $20 from $25) and GSK.

Altimmune Inc (ALT) reported a strong cash position of approximately USD535 million as of April 2026, bolstered by a USD225 million public offering. Despite increased R&D and G&A expenses leading to a net loss of USD22.6 million in Q1 2026, the company's financial runway is secured through the Phase III MASH 52-week data readout in 2029. Pemvidutide, their lead drug candidate, has received Breakthrough Therapy designation, and its Phase II IMPACT trial showed promising efficacy, with Phase III trials aligned with regulatory feedback from the FDA and EMA.